Menu
Submit Data
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

ARA 290

Cibinetide, PHBSP, PH-BSP, Helix B surface peptide

An 11-amino acid peptide derived from erythropoietin, providing tissue protection, anti-inflammation, and neuroprotection without erythropoietic effects.

Molecular Profile
Formula C51H84N16O21
Mol. Weight 1257.3 g/mol
Sequence Gly-Glu-Pro-Pro...
Clinical Data Trials
Scientific Data Studies
Route
Intravenous (IV)
2-4 mg
INT
Subcutaneous (SC)
2-4 mg
SUB

How It Works

How It Works: ARA-290 acts as a selective agonist of the innate repair receptor (IRR), mimicking the tissue-protective effects of erythropoietin to reduce inflammation and promote healing without affecting hematopoiesis.

  • Binds to the IRR heterocomplex of EPOR and β-common receptor, activating protective signaling pathways.
  • Suppresses production of pro-inflammatory cytokines such as TNF-α and IL-6.
  • Enhances cell survival, anti-apoptotic effects, and tissue repair in neuropathic and inflammatory conditions.
  • Improves metabolic control and reduces neuropathic pain in conditions like diabetes and sarcoidosis.

Pairs Well With

TB
TB-500
Systemic repair
Cu
GHK-Cu
Skin & collagen
KP
KPV
Anti-inflammatory
Ip
Ipamorelin
GH secretagogue

Latest Clinical Trials

Unknown PHASE2 NCT01933529

ARA290 in T2D (Effects of ARA 290, an Erythropoietin Analogue) in Prediabetes and Type 2 Diabetes)

Claes-Göran Östenson
INTERVENTIONAL
Updated Dec 15, 2025
Completed PHASE3 NCT02638337

Study to Evaluate Ospemifene in Patients With Moderate to Severe Vaginal Dryness Due to Menopause

Shionogi
INTERVENTIONAL
Updated Dec 15, 2025
Completed PHASE2 NCT02039687

Study of Efficacy of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms of Subjects With Sarcoidosis

Araim Pharmaceuticals, Inc.
INTERVENTIONAL
Updated Dec 15, 2025
View All Clinical Trials

Latest Studies

Utility 2
pubmed Jan 2, 2025

Anti-Inflammatory Effects of Clarstatin, a Shared-Epitope-Antagonistic Cyclic Peptide, on Experimental Autoimmune Uveitis in Mice.

Merzbach. Shira S; Schumacher-Klinger. Adi A; Klazas. Michal M; Hoffman. Amnon A...

A lab-made cyclic peptide called Clarstatin was given to mice with an eye inflammation model. It cut the disease severity by 30‑80% and lowered key inflammatory signals, doing about as well as steroids. The work shows the peptide can act as an anti‑inflammatory agent in animals, but it’s still far from being a usable supplement or drug for people.

Utility 2
pubmed Jun 28, 2024

The protective effect of erythropoietin and its novel derived peptides in peripheral nerve injury.

Liu. Guixian G; Liang. Jie J; Li. Wei W; Jiang. Suli S; Song. Meiying M; Xu. Shu...

Erythropoietin (EPO) does more than boost red blood cells—it can protect nerves. Because regular EPO can cause side effects when used long‑term, scientists made smaller peptide versions like ARA290 that keep the protective benefits but are safer. ARA290, however, disappears from the body quickly, so researchers created a modified version called CHBP that lasts longer. The review highlights these peptides as promising future drugs for nerve injury, but they’re still experimental.

Utility 2
pubmed Mar 1, 2024

Erythropoietin-derived peptide ARA290 mediates brain tissue protection through the β-common receptor in mice with cerebral ischemic stroke.

Wang. Rong-Liang RL; Yang. Zhen-Hong ZH; Huang. Yu-You YY; Hu. Yue Y; Wang. Yi-L...

In mice that had a stroke, a short peptide called ARA290 protected brain cells and improved neurological scores. It worked through a specific receptor (β‑common receptor) and, unlike the full hormone erythropoietin, it didn’t boost red‑blood‑cell production. When that receptor was blocked, the protection disappeared.

Browse All Studies